{"object":"list","generated_at":"2026-11-14T13:25:49.150645Z","window_hours":48,"domain":null,"category":null,"count":20,"items":[{"id":"53150ae6-1fa2-418b-ae1b-37f3f8c286ec","title":"Google Research releases Antigravity teamwork and Gemini 4 for scientific problem solving","summary":"According to Google Research: Google Research reports recent results from Antigravity's teamwork multiagent systems combined with Gemini 4 models, which tackle complex problems across mathematics, computer science, and engineering. According to Google, these tools pair parallel generation with dedicated verifiers to bridge the gap in model predictability and partition context to maintain multi-day task accuracy. Google is making these agentic tools available externally to researchers and developers.","source":"Google Research","source_url":"https://research.google/blog/advancing-science-engineering-with-antigravitys-teamwork-feature/","canonical_url":"https://polyemergence.com/en/archive/2026/11/14/53150ae6-1fa2-418b-ae1b-37f3f8c286ec/","language":"en","category":"models","domain":"ai","related_domains":[],"evidence":{"type":"official_release","stage":"unspecified"},"reading_context":"","importance":95,"scores":{"signal":90,"structure":95,"consequence":100,"confidence":87,"momentum":85},"published_at":"2026-11-13T20:47:18Z","source_published_at":"2026-11-13T20:47:18Z","date_basis":"source_published","first_seen_at":"2026-11-13T23:24:00.054473Z","tags":["multiagent systems","gemini 4","formal verification","lean 4","scientific discovery"]},{"id":"23a1cdb9-f44d-4841-a368-274b49cc290f","title":"Jensen Huang Steps Down as NVIDIA CEO","summary":"NVIDIA announces that Jensen Huang has stepped down from his roles as president, CEO, and board director, with immediate effect. Colette Kress has been appointed as interim CEO while the board searches for a permanent successor.","source":"QbitAI 量子位","source_url":"https://www.qbitai.com/2026/11/509995.html","canonical_url":"https://polyemergence.com/en/archive/2026/11/13/23a1cdb9-f44d-4841-a368-274b49cc290f/","language":"en","category":"company","domain":"ai","related_domains":[],"evidence":{"type":"media_report","stage":"unspecified"},"reading_context":"","importance":90,"scores":{"signal":95,"structure":90,"consequence":85,"confidence":93,"momentum":95},"published_at":"2026-11-13T09:02:39Z","source_published_at":"2026-11-13T09:02:39Z","date_basis":"source_published","first_seen_at":"2026-11-13T14:10:09.890334Z","tags":["nvidia","jensen huang","ceo transition","colette kress"]},{"id":"8bd8121f-5602-4839-b3f7-c08af3475663","title":"Jensen Huang leaves Nvidia after 33 years","summary":"Nvidia CEO Jensen Huang has left the company following scandals, marking the end of an era for Big Tech. While analysts say Nvidia's product roadmap and supply chain remain solid through 2027, the company faces a major challenge in finding a successor with his visionary leadership and willingness to make massive long-term bets.","source":"The Verge AI","source_url":"https://www.theverge.com/tech/1033781/nvidia-jensen-huang-last-visionary-showman-founder-ceo","canonical_url":"https://polyemergence.com/en/archive/2026/11/14/8bd8121f-5602-4839-b3f7-c08af3475663/","language":"en","category":"company","domain":"ai","related_domains":[],"evidence":{"type":"media_report","stage":"unspecified"},"reading_context":"","importance":88,"scores":{"signal":90,"structure":90,"consequence":83,"confidence":85,"momentum":95},"published_at":"2026-11-14T12:00:00Z","source_published_at":"2026-11-14T12:00:00Z","date_basis":"source_published","first_seen_at":"2026-11-14T13:05:37.169350Z","tags":["nvidia","jensen huang","leadership","semiconductors","artificial intelligence"]},{"id":"ef947a5d-9a1d-4aaf-a3a3-fad2dc5bef6a","title":"Google Introduces Gemini 4 Hydrogen Model for Fast Execution and Agentic Workflows","summary":"According to Google DeepMind: Google is introducing Gemini 4 Hydrogen, a new model designed for rapid execution and everyday agentic workflows. Available across Google AI Studio, the Gemini API, and the Gemini app, Hydrogen offers flat pricing at $1.50 per million input tokens and $7.50 per million output tokens while delivering significant speed and efficiency upgrades over its predecessor.","source":"Google DeepMind","source_url":"https://deepmind.google/blog/introducing-gemini-4-hydrogen/","canonical_url":"https://polyemergence.com/en/archive/2026/11/13/ef947a5d-9a1d-4aaf-a3a3-fad2dc5bef6a/","language":"en","category":"models","domain":"ai","related_domains":[],"evidence":{"type":"official_release","stage":"unspecified"},"reading_context":"","importance":88,"scores":{"signal":90,"structure":85,"consequence":90,"confidence":92,"momentum":95},"published_at":"2026-11-12T18:00:50Z","source_published_at":"2026-11-12T18:00:50Z","date_basis":"source_published","first_seen_at":"2026-11-12T23:24:35.533918Z","tags":["google","gemini","ai model","llm","agentic workflows"]},{"id":"0b29db07-505d-4630-a996-8af53a881290","title":"Release v5.23.0 - New Model Additions and Exporters Update","summary":"Hugging Face Transformers version 5.23.0 introduces a variety of new multi-modal and language models, including Inkling2, Liquid AI's LFM3, and InternLM3. It also overhauls the model exporters, allowing users to seamlessly export and run models on optimized runtimes like ONNX Runtime and OpenVINO with significant speed improvements.","source":"Hugging Face Transformers Releases","source_url":"https://github.com/huggingface/transformers/releases/tag/v5.23.0","canonical_url":"https://polyemergence.com/en/archive/2026/11/13/0b29db07-505d-4630-a996-8af53a881290/","language":"en","category":"open_source","domain":"ai","related_domains":[],"evidence":{"type":"open_source","stage":"unspecified"},"reading_context":"","importance":87,"scores":{"signal":90,"structure":90,"consequence":80,"confidence":93,"momentum":90},"published_at":"2026-11-13T14:10:57Z","source_published_at":"2026-11-13T14:10:57Z","date_basis":"source_published","first_seen_at":"2026-11-13T23:26:28.856227Z","tags":["transformers","huggingface","llm","multimodal","open_source"]},{"id":"ddffa2c1-4420-46b0-b5c2-73c0e5ee541d","title":"Nvidia scandal: Howard Lutnick under pressure over alleged lack of action","summary":"US commerce secretary Howard Lutnick is facing intense pressure and potential dismissal following reports that he delayed blacklisting a Singapore-based firm linked to an alleged Chinese spy. The scandal erupted after Jensen Huang resigned as Nvidia CEO amid revelations of personal conduct and national security concerns.","source":"The Guardian AI","source_url":"https://www.theguardian.com/technology/2026/nov/13/nvidia-scandal-sparks-us-national-security-concerns-china","canonical_url":"https://polyemergence.com/en/archive/2026/11/13/ddffa2c1-4420-46b0-b5c2-73c0e5ee541d/","language":"en","category":"company","domain":"ai","related_domains":[],"evidence":{"type":"media_report","stage":"unspecified"},"reading_context":"","importance":86,"scores":{"signal":90,"structure":85,"consequence":82,"confidence":85,"momentum":95},"published_at":"2026-11-13T09:41:22Z","source_published_at":"2026-11-13T09:41:22Z","date_basis":"source_published","first_seen_at":"2026-11-13T14:03:58.903538Z","tags":["nvidia","jensen huang","howard lutnick","export controls","national security"]},{"id":"c0708759-1753-4695-8744-44f2ca8c692a","title":"US Lawmakers Summon Ex-Nvidia CEO After Spy Scandal","summary":"US lawmakers have summoned Nvidia's former CEO to face questions in December following his resignation over extramarital affairs, including one with a suspected Chinese spy. The scandal has wiped nearly half a trillion dollars off Nvidia's market value and triggered national security concerns.","source":"Le Monde AI","source_url":"https://www.lemonde.fr/en/international/article/2026/11/13/us-lawmakers-summon-nvidia-ex-ceo-after-affair-with-suspected-spy_6779566_4.html","canonical_url":"https://polyemergence.com/en/archive/2026/11/13/c0708759-1753-4695-8744-44f2ca8c692a/","language":"en","category":"company","domain":"ai","related_domains":[],"evidence":{"type":"media_report","stage":"unspecified"},"reading_context":"","importance":86,"scores":{"signal":85,"structure":88,"consequence":85,"confidence":81,"momentum":90},"published_at":"2026-11-13T07:37:12Z","source_published_at":"2026-11-13T07:37:12Z","date_basis":"source_published","first_seen_at":"2026-11-13T14:09:09.172836Z","tags":["nvidia","jensen huang","national security","artificial intelligence","us-china relations"]},{"id":"43c21d55-e05f-4146-9961-f987988ab1d9","title":"LLMON: An LLM-Native Markup Language, now in Granite 4.1 3B and 8B","summary":"Researchers have developed LLMON, an LLM-native markup language designed to explicitly communicate structure and semantics to models, bypassing the limitations of traditional JSON. By separating instructions from data using reserved special tokens, the newly released experimental Granite 4.1 LLMON preview models achieve significantly higher resistance to prompt injection attacks while maintaining general capabilities.","source":"Hugging Face","source_url":"https://huggingface.co/blog/ibm-granite/llmon-an-llm-native-markup-language-now-in-granite","canonical_url":"https://polyemergence.com/en/archive/2026/11/13/43c21d55-e05f-4146-9961-f987988ab1d9/","language":"en","category":"models","domain":"ai","related_domains":[],"evidence":{"type":"media_report","stage":"unspecified"},"reading_context":"","importance":85,"scores":{"signal":90,"structure":85,"consequence":80,"confidence":86,"momentum":75},"published_at":"2026-11-12T19:07:35Z","source_published_at":"2026-11-12T19:07:35Z","date_basis":"source_published","first_seen_at":"2026-11-12T23:30:37.241375Z","tags":["llmon","granite","prompt injection","markup language","llm architecture"]},{"id":"65bf8907-9818-4c0f-b41e-800d318a1400","title":"Biopharma industry looks beyond GLP-1s for next-gen weight loss treatments","summary":"At the ObesityWeek 2026 conference, biopharma companies are shifting attention beyond standard GLP-1 drugs to explore new pathways like amylin modulation. Industry experts emphasize that the next generation of weight loss therapies will focus heavily on improving treatment persistence and the quality of weight reduction, particularly preserving muscle mass.","source":"BioSpace Drug Development","source_url":"https://www.biospace.com/drug-development/biopharma-pushes-beyond-glp-1s-weight-loss-at-obesityweek-2026","canonical_url":"https://polyemergence.com/en/archive/2026/11/13/65bf8907-9818-4c0f-b41e-800d318a1400/","language":"en","category":"business","domain":"programmable_life","related_domains":[],"evidence":{"type":"media_report","stage":"unspecified"},"reading_context":"","importance":83,"scores":{"signal":80,"structure":85,"consequence":85,"confidence":85,"momentum":88},"published_at":"2026-11-13T13:15:31Z","source_published_at":"2026-11-13T13:15:31Z","date_basis":"source_published","first_seen_at":"2026-11-13T14:03:04.662291Z","tags":["obesity","amylin","glp-1","weight-loss","biopharma"]},{"id":"d04bdb4f-1549-446e-b58d-ac3ffe76f761","title":"Google Announces 'Gemini 4 Hydrogen', a Fast and Low-Cost Model Available to Free Users","summary":"Google has announced Gemini 4 Hydrogen, a new AI model focused on speed and efficiency for everyday coding and agent tasks. According to Google, it is 2.5 times faster than the previous generation model and is already rolling out globally, including for free users.","source":"ITmedia AI+","source_url":"https://www.itmedia.co.jp/news/article/2611/13/2000003162/","canonical_url":"https://polyemergence.com/en/archive/2026/11/13/d04bdb4f-1549-446e-b58d-ac3ffe76f761/","language":"en","category":"models","domain":"ai","related_domains":[],"evidence":{"type":"unknown","stage":"unspecified"},"reading_context":"","importance":83,"scores":{"signal":85,"structure":80,"consequence":85,"confidence":89,"momentum":88},"published_at":"2026-11-12T23:04:46Z","source_published_at":"2026-11-12T23:04:46Z","date_basis":"source_published","first_seen_at":"2026-11-13T23:33:40.672216Z","tags":["google","gemini","ai model","artificial intelligence","llm"]},{"id":"31709d43-5c04-4ba1-bcc8-5ef8ad929c74","title":"Delix raises $100M for depression drug without psychedelic trips","summary":"Delix Therapeutics has secured $100 million in Series C funding to advance zalsupindole, a non-hallucinatory psychedelic therapy designed to treat major depressive disorder. Backed by Johnson & Johnson, the company plans to start a Phase 2b clinical trial in 2027.","source":"Fierce Biotech","source_url":"https://www.fiercebiotech.com/biotech/delix-drums-100m-its-non-hallucinatory-psychedelic-therapy-depression","canonical_url":"https://polyemergence.com/en/archive/2026/11/13/31709d43-5c04-4ba1-bcc8-5ef8ad929c74/","language":"en","category":"startups","domain":"programmable_life","related_domains":[],"evidence":{"type":"media_report","stage":"unspecified"},"reading_context":"","importance":82,"scores":{"signal":80,"structure":85,"consequence":80,"confidence":87,"momentum":85},"published_at":"2026-11-13T14:02:59.484515Z","source_published_at":"2026-11-13T14:02:59.484515Z","date_basis":"source_published","first_seen_at":"2026-11-13T14:04:21.009478Z","tags":["delix therapeutics","depression","psychedelics","neuroplasticity","clinical trial"]},{"id":"88267556-62e5-4a80-9d5e-abbe2a3d5ba9","title":"Experts fear Treasury's proposed China biotech investment ban will backfire on U.S. leadership","summary":"The U.S. Treasury's proposed rules to restrict outbound investments in China's biopharma sector have sparked intense concern among industry leaders and legal experts. While Washington aims to protect national and economic security, critics like RA Capital's Peter Kolchinsky warn that the vague regulations—particularly around joint ventures—will blind U.S. investors, cripple domestic innovation, and inadvertently hand a competitive advantage to European and Chinese rivals.","source":"Fierce Biotech","source_url":"https://www.fiercebiotech.com/biotech/treasury-coins-act-proposal-pharmaceuticals-china-newco-legal-maze-biotech-vc-warnings","canonical_url":"https://polyemergence.com/en/archive/2026/11/14/88267556-62e5-4a80-9d5e-abbe2a3d5ba9/","language":"en","category":"business","domain":"programmable_life","related_domains":[],"evidence":{"type":"media_report","stage":"unspecified"},"reading_context":"","importance":79,"scores":{"signal":80,"structure":85,"consequence":70,"confidence":84,"momentum":75},"published_at":"2026-11-13T23:31:17.966690Z","source_published_at":"2026-11-13T23:31:17.966690Z","date_basis":"source_published","first_seen_at":"2026-11-13T23:33:04.142512Z","tags":["biotech","investment ban","china","regulation","pharma"]},{"id":"f0120458-5edd-44f6-8bf0-564d74bbd709","title":"AI makes companies flatter, but also more bureaucratic","summary":"As AI slashes the cost of monitoring and data analysis, companies are flattening their management hierarchies while simultaneously extending rules into every daily detail. While headquarters gain real-time visibility over operations, front-line workers face a barrage of automated checks and daily tasks, which risks suppressing worker initiative and choking off business exploration.","source":"TMTPost 钛媒体","source_url":"https://www.tmtpost.com/8205239.html","canonical_url":"https://polyemergence.com/en/archive/2026/11/14/f0120458-5edd-44f6-8bf0-564d74bbd709/","language":"en","category":"society","domain":"ai","related_domains":[],"evidence":{"type":"media_report","stage":"unspecified"},"reading_context":"","importance":78,"scores":{"signal":75,"structure":80,"consequence":80,"confidence":84,"momentum":70},"published_at":"2026-11-14T07:21:00Z","source_published_at":"2026-11-14T07:21:00Z","date_basis":"source_published","first_seen_at":"2026-11-14T13:06:20.999650Z","tags":["artificial intelligence","enterprise management","bureaucracy","workplace","automation"]},{"id":"26764bf6-548a-41d7-bf28-86b720e75259","title":"Bill Gates-backed Breakthrough Energy says global decarbonization would cost 7.5 trillion dollars","summary":"According to MIT Climate: At an MIT energy conference, Breakthrough Energy CTO Eric Toone reported that global decarbonization would cost roughly 7.5 trillion dollars, or 5 percent of world GDP. Utilizing artificial intelligence to analyze costs, the firm emphasizes that success relies heavily on eliminating the green premium because people are generally unwilling to pay extra for eco-friendly alternatives.","source":"MIT Climate","source_url":"https://news.mit.edu/2026/energy-prosperity-emissions-innovation-decarbonization-progress-report-1112","canonical_url":"https://polyemergence.com/en/archive/2026/11/13/26764bf6-548a-41d7-bf28-86b720e75259/","language":"en","category":"business","domain":"climate_water_environment","related_domains":["ai"],"evidence":{"type":"official_release","stage":"unspecified"},"reading_context":"","importance":77,"scores":{"signal":75,"structure":80,"consequence":75,"confidence":87,"momentum":70},"published_at":"2026-11-12T21:30:00Z","source_published_at":"2026-11-12T21:30:00Z","date_basis":"source_published","first_seen_at":"2026-11-12T23:20:33.974464Z","tags":["decarbonization","clean energy","breakthrough energy","climate tech","artificial intelligence"]},{"id":"3e49b2e4-0b74-47fc-a6c0-46903b661405","title":"AI Is Rocking the Literary World","summary":"Artificial intelligence is quietly transforming the literary world, helping some authors churn out hundreds of novels while sparking massive controversies. Publishers, agents, and writers are grappling with rampant AI use, copyright hurdles, and a wave of false accusations that have derailed major book deals. While tech enthusiasts see a new creative tool, many writers fear it will undercut human creativity and flood the market with machine-made stories.","source":"The Guardian AI","source_url":"https://www.theguardian.com/books/ng-interactive/2026/nov/14/its-like-the-wild-west-how-ai-has-rocked-the-literary-world","canonical_url":"https://polyemergence.com/en/archive/2026/11/14/3e49b2e4-0b74-47fc-a6c0-46903b661405/","language":"en","category":"society","domain":"ai","related_domains":[],"evidence":{"type":"media_report","stage":"unspecified"},"reading_context":"","importance":75,"scores":{"signal":70,"structure":80,"consequence":75,"confidence":85,"momentum":90},"published_at":"2026-11-14T09:00:40Z","source_published_at":"2026-11-14T09:00:40Z","date_basis":"source_published","first_seen_at":"2026-11-14T13:05:10.438019Z","tags":["artificial intelligence","publishing","copyright","generative ai","literature"]},{"id":"2349bf26-1119-4291-83be-49fbaf3b453d","title":"ChatGPT Wallet lets OpenAI's Dots agents buy things for you","summary":"OpenAI is launching ChatGPT Wallet for its US Pro subscribers, allowing its Dots AI agents to make online purchases. The system uses biometric verification for every transaction and generates payment tokens so your actual credit card details are never shared. In the future, OpenAI plans to let users fully delegate purchases by setting strict limits and pre-approval rules.","source":"The Verge AI","source_url":"https://www.theverge.com/ai-artificial-intelligence/1033425/openai-chatgpt-wallet","canonical_url":"https://polyemergence.com/en/archive/2026/11/14/2349bf26-1119-4291-83be-49fbaf3b453d/","language":"en","category":"models","domain":"ai","related_domains":[],"evidence":{"type":"media_report","stage":"unspecified"},"reading_context":"","importance":75,"scores":{"signal":80,"structure":75,"consequence":70,"confidence":85,"momentum":80},"published_at":"2026-11-13T20:45:10Z","source_published_at":"2026-11-13T20:45:10Z","date_basis":"source_published","first_seen_at":"2026-11-13T23:32:07.806901Z","tags":["chatgpt wallet","openai","ai agents","payments","ecommerce"]},{"id":"f1affa86-d8a2-4305-8eb6-5c991596b63c","title":"LangChain Raises $300M Series C at $3B Valuation","summary":"According to LangChain Blog: LangChain announced a $300M Series C funding round led by CapitalG, valuing the company at $3B. The company aims to help enterprises own their intelligence through AI agents and its LangSmith platform, which is already used by over 7,000 organizations.","source":"LangChain Blog","source_url":"https://www.langchain.com/blog/series-c","canonical_url":"https://polyemergence.com/en/archive/2026/11/13/f1affa86-d8a2-4305-8eb6-5c991596b63c/","language":"en","category":"business","domain":"ai","related_domains":[],"evidence":{"type":"official_release","stage":"unspecified"},"reading_context":"","importance":75,"scores":{"signal":70,"structure":80,"consequence":75,"confidence":89,"momentum":85},"published_at":"2026-11-13T15:55:00Z","source_published_at":"2026-11-13T15:55:00Z","date_basis":"source_published","first_seen_at":"2026-11-13T23:25:13.133081Z","tags":["langchain","langsmith","ai agents","funding","enterprise ai"]},{"id":"03ab4029-28f7-4d87-b6b0-900f1e7c84bd","title":"Merck’s MASH drug efinopegdutide succeeds in mid-stage trial","summary":"Merck reports that its experimental drug efinopegdutide successfully treated MASH (metabolic dysfunction-associated steatohepatitis) in a mid-stage clinical trial. The drug outperformed a placebo by helping clear the liver disease in over half of the tested patients without worsening liver scarring.","source":"Fierce Biotech","source_url":"https://www.fiercebiotech.com/biotech/mercks-mash-hopeful-efinopegdutide-wins-mid-stage-study","canonical_url":"https://polyemergence.com/en/archive/2026/11/13/03ab4029-28f7-4d87-b6b0-900f1e7c84bd/","language":"en","category":"company","domain":"programmable_life","related_domains":[],"evidence":{"type":"media_report","stage":"unspecified"},"reading_context":"","importance":75,"scores":{"signal":80,"structure":75,"consequence":70,"confidence":84,"momentum":75},"published_at":"2026-11-13T14:02:59.484507Z","source_published_at":"2026-11-13T14:02:59.484507Z","date_basis":"source_published","first_seen_at":"2026-11-13T14:05:12.009611Z","tags":["mash","efinopegdutide","merck","glp-1","clinical trial"]},{"id":"3554c610-387a-4ade-865e-178a96dc4347","title":"Cohere Expands Sovereign AI Platform with AISLE and cubic","summary":"According to Cohere Blog: Cohere announces the completion of its acquisition of AISLE and the onboarding of the team behind cubic. These additions form the core of Cohere's newly established cybersecurity business and secure coding vertical, aimed at helping enterprises and governments deploy AI while retaining full control over data and infrastructure.","source":"Cohere Blog","source_url":"https://cohere.com/blog/cohere-expands-its-sovereign-ai-platform-with-aisle-and-cubic","canonical_url":"https://polyemergence.com/en/archive/2026/11/13/3554c610-387a-4ade-865e-178a96dc4347/","language":"en","category":"company","domain":"ai","related_domains":[],"evidence":{"type":"official_release","stage":"unspecified"},"reading_context":"","importance":75,"scores":{"signal":70,"structure":80,"consequence":75,"confidence":91,"momentum":70},"published_at":"2026-11-13T14:00:00Z","source_published_at":"2026-11-13T14:00:00Z","date_basis":"source_published","first_seen_at":"2026-11-13T23:25:32.775971Z","tags":["cohere","aisle","cubic","sovereign ai","cybersecurity"]},{"id":"a5e14d0a-2f40-4194-ab3d-11a44eef89b7","title":"Regeneron's antibody curbs POTS heart rate spikes in mid-stage trial","summary":"Regeneron announced that its experimental monoclonal antibody, baloncibart, met its primary goal in a Phase 2 trial for postural orthostatic tachycardia syndrome, a chronic condition with no FDA-approved treatments. Patients receiving a single high dose experienced a mean drop in heart rate of 11.4 beats per minute compared to placebo, paving the way for a Phase 3 study planned for early 2027.","source":"BioSpace Drug Development","source_url":"https://www.biospace.com/drug-development/regenerons-pots-antibody-curbs-heart-rate-spikes-teeing-up-phase-3-trial","canonical_url":"https://polyemergence.com/en/archive/2026/11/13/a5e14d0a-2f40-4194-ab3d-11a44eef89b7/","language":"en","category":"company","domain":"programmable_life","related_domains":[],"evidence":{"type":"media_report","stage":"unspecified"},"reading_context":"","importance":75,"scores":{"signal":75,"structure":70,"consequence":80,"confidence":82,"momentum":70},"published_at":"2026-11-13T13:59:44Z","source_published_at":"2026-11-13T13:59:44Z","date_basis":"source_published","first_seen_at":"2026-11-13T14:02:46.179133Z","tags":["regeneron","pots","monoclonal antibody","clinical trial","baloncibart"]}],"methodology_url":"https://polyemergence.com/api/v1/methodology"}